Recombinant factor IX Fc for the treatment of hemophilia B
European Journal of Haematology · 2024-05 · 112 (5) · 678-691
DOI: 10.1111/ejh.14176 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 18.02.2024. Verfasst von Rolf Ljung und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences-Pediatrics, Lund University, Lund, Sweden. Hauptthemen laut MEDLINE: Factor IX, Hemophilia B. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sobi, Sanofi, Swedish Orphan Biovitrum.
Abstract (Originalsprache)
Current hemophilia B treatment guidelines recommend routine prophylaxis with factor IX (FIX) replacement products, tailored to maintain plasma activity at levels that will prevent bleeds. However, plasma FIX activity may not be the primary determinant or best indicator of hemostatic efficacy due to its extravascular distribution. FIX replacement therapy has evolved to include extended half‐life (EHL) products that provide effective bleed protection when administered at intervals of 7 days or longer. rFIXFc is a recombinant fusion protein with an extended circulation time. rFIXFc has a biodistribution profile consistent with distribution into extravascular space, where it may support hemostasis at sites of vessel injury independent of circulating plasma activity levels. The safety and efficacy of rFIXFc prophylaxis is well established in adults, adolescents and children including previously untreated patients with hemophilia B, with substantial evidence from clinical trials and real‐world clinical practice. This review describes the pharmacokinetic characteristics of rFIXFc, summarizes available safety and efficacy data, and evaluates the use of rFIXFc in special populations. Current hemophilia B treatment challenges, including target FIX plasma levels, perioperative use, and management of patients with comorbidities, are discussed together with the potential role of EHL products in the future treatment landscape of hemophilia B.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences-Pediatrics, Lund University, Lund, Sweden.
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
- Indiana Hemophilia & Thrombosis Center, Inc, Indianapolis, Indiana, USA.
ORCID-Profile: Rolf Ljung, Davide Matino, Amy D Shapiro
Förderung
- Sobi
- Sanofi
- Swedish Orphan Biovitrum
Zitieren
APA
Ljung, R., Matino, D., & Shapiro, A. D. (2024). Recombinant factor IX Fc for the treatment of hemophilia B. European Journal of Haematology, 112(5), 678-691. https://doi.org/10.1111/ejh.14176
Vancouver
Ljung R, Matino D, Shapiro AD. Recombinant factor IX Fc for the treatment of hemophilia B. European Journal of Haematology. 2024;112(5):678-691. doi:10.1111/ejh.14176
BibTeX
@article{Ljung2024,
author = {Ljung, Rolf and Matino, Davide and Shapiro, Amy D},
title = {Recombinant factor IX Fc for the treatment of hemophilia B},
journal = {European Journal of Haematology},
year = {2024},
volume = {112},
number = {5},
pages = {678--691},
doi = {10.1111/ejh.14176}
}
EUVIMED